Cargando…

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden neutralizing responses. To assess the contribution of vaccines and natural infection, we cross-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pradenas, Edwards, Marfil, Silvia, Urrea, Víctor, Trigueros, Macedonia, Pidkova, Tetyana, Pons-Grífols, Anna, Ortiz, Raquel, Rovirosa, Carla, Tarrés-Freixas, Ferran, Aguilar-Gurrieri, Carmen, Toledo, Ruth, Chamorro, Anna, Noguera-Julian, Marc, Mateu, Lourdes, Blanco, Ignacio, Grau, Eulàlia, Massanella, Marta, Carrillo, Jorge, Clotet, Bonaventura, Trinité, Benjamin, Blanco, Julià
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027310/ https://www.ncbi.nlm.nih.gov/pubmed/36999095 http://dx.doi.org/10.1016/j.isci.2023.106457

Ejemplares similares

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
por: Pradenas, Edwards, et al.
Publicado: (2022)

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
por: Abella, Eugenia, et al.
Publicado: (2022)

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity
por: Ortiz, Raquel, et al.
Publicado: (2023)

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities
por: Trigueros, Macedonia, et al.
Publicado: (2022)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
por: Trinité, Benjamin, et al.
Publicado: (2021)

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
por: Felip, Eudald, et al.
Publicado: (2022)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
por: Trinité, Benjamin, et al.
Publicado: (2021)

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
por: Pradenas, Edwards, et al.
Publicado: (2021)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2023)

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
por: Pradenas, Edwards, et al.
Publicado: (2022)

Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
por: Aguilar-Gurrieri, Carmen, et al.
Publicado: (2023)

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
por: Garcia-Cirera, Silvia, et al.
Publicado: (2022)

First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
por: Fernández-Bastit, Leira, et al.
Publicado: (2021)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2022)

Low levels of anti-MPER antibodies are detectable in viremic HIV infected
por: Carrillo, J, et al.
Publicado: (2012)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

On the steps of cell-to-cell HIV transmission between CD4 T cells
por: Puigdomènech, Isabel, et al.
Publicado: (2009)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
por: Massanella, Marta, et al.
Publicado: (2021)

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
por: Carrillo, Jorge, et al.
Publicado: (2021)

Restricted infection of xenotropic murine leukemia virus-related virus in human lymphoid tissue
por: Curriu, Marta, et al.
Publicado: (2011)

Antiretroviral therapy suppressed participants with low CD4(+) T-cell counts segregate according to opposite immunological phenotypes
por: Pérez-Santiago, Josué, et al.
Publicado: (2016)

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART
por: Puertas, Maria C., et al.
Publicado: (2016)

Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors
por: Kilpeläinen, Athina, et al.
Publicado: (2022)

P04-13. Complex pattern of neutralization of cell-to-cell HIV transmission to activated CD4+T cells
por: Massanella, M, et al.
Publicado: (2009)

Comparison of Reverse Transcription (RT)-Quantitative PCR and RT-Droplet Digital PCR for Detection of Genomic and Subgenomic SARS-CoV-2 RNA
por: Morón-López, Sara, et al.
Publicado: (2023)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission
por: Perez-Zsolt, Daniel, et al.
Publicado: (2021)

Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery
por: Massanella, Marta, et al.
Publicado: (2015)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
por: Ainsua-Enrich, Erola, et al.
Publicado: (2022)

Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
por: Carrillo, Jorge, et al.
Publicado: (2018)

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals
por: Massanella, Marta, et al.
Publicado: (2014)

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2021)

Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2022)

HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4
por: Puigdomènech, Isabel, et al.
Publicado: (2008)

Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function
por: Curriu, Marta, et al.
Publicado: (2012)

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
por: Cunyat, Francesc, et al.
Publicado: (2012)

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, Anuska, et al.
Publicado: (2013)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dk4vdkaecf6q10r405lbc0fmrk